Profile - To The Moon

Charllote

Posts · 19Posts · 19
Following · 0Following · 0
Followers · 0Followers · 0

- CharlloteCharllote
  ·2022-06-27
  its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy] [Happy]
  Sorry, this post has been deleted
  1.90K Comment
  1
  Share
  Report
- CharlloteCharllote
  ·2022-06-19
  good and like
  Nasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip
  These fast-paced companies are ripe for the picking following a peak decline of 33% for the Nasdaq.
  Nasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip
  1.38K Comment
  1
  Share
  Report
- CharlloteCharllote
  ·2022-04-14
  Gogoogog
  Skittish Stock Traders Are Bracing for $2 Trillion Option Expiration
  BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for
  Skittish Stock Traders Are Bracing for $2 Trillion Option Expiration
  2.54K Comment
  4
  Share
  Report
- CharlloteCharllote
  ·2021-12-30
  Ok
  Sorry, this post has been deleted
  1.98K Comment
  3
  Share
  Report
- CharlloteCharllote
  ·2021-12-30
  Ok
  Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade
  These two stocks could provide life-changing returns in 10 years.
  Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade
  1.65K Comment
  1
  Share
  Report
- CharlloteCharllote
  ·2021-12-30
  Ok
  Biogen Dropped 5% in Premarket Trading
  U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying
  Biogen Dropped 5% in Premarket Trading
  1.26K Comment
  3
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3585210989099593","uuid":"3585210989099593","gmtCreate":1622647388502,"gmtModify":1630649717890,"name":"Charllote","pinyin":"charllote","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":31,"headSize":13,"tweetSize":19,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.07","exceedPercentage":"93.66%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9046139991,"gmtCreate":1656307439413,"gmtModify":1676535803653,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3585210989099593","idStr":"3585210989099593"},"themes":[],"htmlText":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy]&nbsp;[Happy]&nbsp;","listText":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy]&nbsp;[Happy]&nbsp;","text":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9046139991","repostId":"1173489822","repostType":2,"isVote":1,"tweetType":1,"viewCount":1904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9040385427,"gmtCreate":1655609539369,"gmtModify":1676535671062,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3585210989099593","idStr":"3585210989099593"},"themes":[],"htmlText":"good and like","listText":"good and like","text":"good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9040385427","repostId":"2244108696","repostType":2,"repost":{"id":"2244108696","kind":"highlight","pubTimestamp":1655599329,"share":"https://ttm.financial/m/news/2244108696?lang=&edition=fundamental","pubTime":"2022-06-19 08:42","market":"us","language":"en","title":"Nasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2244108696","media":"Motley Fool","summary":"These fast-paced companies are ripe for the picking following a peak decline of 33% for the Nasdaq.","content":"<div>\n<p>This year has offered a not-so-subtle reminder to Wall Street and the investing community that stocks don't move upward in a straight line. Since hitting their all-time closing highs, the widely ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/18/nasdaq-bear-market-4-growth-stocks-regret-not-buy/\">Web Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-19 08:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/18/nasdaq-bear-market-4-growth-stocks-regret-not-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This year has offered a not-so-subtle reminder to Wall Street and the investing community that stocks don't move upward in a straight line. Since hitting their all-time closing highs, the widely ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/18/nasdaq-bear-market-4-growth-stocks-regret-not-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AI":"C3.ai, Inc.","BK4504":"桥水持仓","BK4166":"消费信贷","BK4142":"酒店、度假村与豪华游轮","BK4566":"资本集团","BK4548":"巴美列捷福持仓","ISRG":"直觉外科公司","BK4551":"寇图资本持仓","BK4023":"应用软件","BK4561":"索罗斯持仓","BK4581":"高盛持仓","BK4554":"元宇宙及AR概念","BK4543":"AI","ABNB":"爱彼迎","BK4534":"瑞士信贷持仓","BK4503":"景林资产持仓","UPST":"Upstart Holdings, Inc.","BK4106":"数据处理与外包服务","BK4528":"SaaS概念","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓","BK4082":"医疗保健设备"},"source_url":"https://www.fool.com/investing/2022/06/18/nasdaq-bear-market-4-growth-stocks-regret-not-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2244108696","content_text":"This year has offered a not-so-subtle reminder to Wall Street and the investing community that stocks don't move upward in a straight line. Since hitting their all-time closing highs, the widely followed Dow Jones Industrial Average, benchmark S&P 500, and growth stock-fueled Nasdaq Composite (^IXIC 1.43%) have respectively tumbled by 17%, 22%, and 33%. These moves squarely put the S&P 500 and Nasdaq in a bear market.There's no question that the velocity and unpredictability of downward moves during a bear market can weigh on investors' psyche. However, it's important to note that every notable decline in the major U.S. indexes, including the Nasdaq Composite, has eventually been cleared away by a bull market. This makes corrections and bear markets the opportune time to put your money to work.With the Nasdaq tumbling, a number of innovative growth stocks now look like incredible deals. What follows are four remarkable growth stocks you'll regret not buying on the dip.BlockThe first exceptionally innovative company investors can confidently buy during the Nasdaq bear market decline is fintech stock Block (SQ 1.74%), the company formerly known as Square. Although cryptocurrency weakness could hurt Bitcoin trading revenue in the near term, and high inflation is bad news for low-income consumers, there are more than enough long-term catalysts for Block to deliver jaw-dropping growth.For more than a decade, the company's foundation has been its seller ecosystem, commonly referred to as the \"Square ecosystem.\" This is the segment that provides point-of-sale solutions, loans, and analytics to businesses to help them succeed. In 2012, just $6.5 billion in gross payment volume (GPV) was processed by the Square ecosystem. But based on the $39.5 billion in GPV in during the first quarter of 2022, the Square ecosystem is on pace for $158 billion in annual GPV.What's particularly interesting about the seller ecosystem is that it's attracting bigger businesses that have higher annualized GPVs. Since this is predominantly a fee-driven operating segment, bigger business should lead to higher gross profit.The other key for Block is digital peer-to-peer payment platform Cash App. In the four years between the end of 2017 and end of 2021, the number of monthly transacting users on Cash App soared from 7 million to north of 44 million. With the recent acquisition of buy now, pay later company Afterpay, Block has the ability to create a closed-loop payment network with its Square ecosystem.AirbnbA second remarkable growth stock that you'll be kicking yourself if you don't buy on this Nasdaq bear market decline is travel and hosting company Airbnb (ABNB 6.68%). Even with recession fears rising and inflation biting consumers' wallets hard in the short term, Airbnb has \"industry disruptor\" written all over it.To begin with, Airbnb is unquestionably a popular alternative to traditional hotels. The Airbnb marketplace provides abundant choice, with properties that often provide a lower cost and added privacy, compared to staying in a hotel in or near a major city. In 2016, the entire platform recognized 52 million total nights and experiences booked. In just the first quarter of 2022, Airbnb practically doubled this figure, with 102.1 million nights and experiences booked.Arguably the most exciting thing about Airbnb is that long-term stays are its fastest-growing category. A \"long-term stay\" is defined as a booking of 28 or more days. In the wake of the pandemic, we've witnessed workforces becoming more mobile. These remote workers seem to be Airbnb's key to sustainably growing its hosting marketplace.Additionally, the company wants a larger piece of the $8 trillion travel industry pie. Airbnb's \"experiences\" segment is working with local experts to lead travelers on adventures, and is likely just scratching the surface with regard to its partnership potential.Image source: Getty Images.Intuitive SurgicalAnother sensational growth stock investors would be wise to scoop up on the Nasdaq bear market dip is robotic-assisted surgical system developer Intuitive Surgical (ISRG 0.72%).One reason for investors to trust Intuitive Surgical over the long haul is its market dominance. When the first quarter came to a close, the company had 6,920 of its da Vinci surgical systems installed in hospitals and surgical centers worldwide. This number may not sound like a lot, but it's many times higher than those of its closest competitors. What's more, these systems are costly ($0.5 million to $2.5 million) and the training for them is time-consuming. In other words, da Vinci buyers tend to remain clients for a long time.Intuitive Surgical's razor-and-blades operating model is also designed to emphasize operating-margin growth over time. During the 2000s, most of the company's sales originated from selling its pricey, but generally low-margin, da Vinci systems. Nowadays, instruments sold with each procedure and system servicing account for the lion's share of total sales. These are higher-margin operating segments. As the company's installed base of systems grows, profits should increase at an even faster pace.There's also a long runway for da Vinci to become a standard of care in the operating room. While it's already a leader in urology and gynecology procedures, there's plenty of room for expansion in colorectal, thoracic, and general soft-tissue surgical procedures.Upstart HoldingsA fourth and final remarkable growth stock that you'll regret not buying on the dip is cloud-based lending platform Upstart Holdings (UPST 9.54%). Even though Wall Street is leery of the unproven Upstart as interest rates rise and fears of a U.S. recession grow, there are multiple aspects of the company's operating model that suggest it could thrive.Perhaps the biggest differentiator for Upstart is its artificial intelligence (AI)-powered lending platform. Rather than relying on the same vetting process for loans that financial institutions have leaned on for decades, Upstart uses AI. This led to 74% of all loans on its platform being fully automated during the first quarter. Automation ultimately saves financial institutions time and money.To build on this point, Upstart's AI-fueled lending platform is opening up opportunities for previously underbanked people. Although the average credit score of Upstart's approvals has been below the average credit score of approvals in the traditional vetting process, there's been no discernible difference in delinquency rates. Even if interest rates continue to rise rapidly, this distinction makes it more likely that financial institutions will turn to Upstart for its AI-based loan-vetting platform.As if this weren't enough to get excited about, Upstart has also moved beyond the personal loan arena and into the auto loan origination market. The auto loan market was recently a $751 billion opportunity -- or about 6.7 times more than the personal loan market Upstart has catered to since its inception.","news_type":1,"symbols_score_info":{"SQ":0.9,"ABNB":0.9,"ISRG":0.83,"UPST":0.9,"AI":1}},"isVote":1,"tweetType":1,"viewCount":1383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9080407091,"gmtCreate":1649902566419,"gmtModify":1676534603298,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3585210989099593","idStr":"3585210989099593"},"themes":[],"htmlText":"Gogoogog","listText":"Gogoogog","text":"Gogoogog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9080407091","repostId":"1153344302","repostType":4,"repost":{"id":"1153344302","kind":"news","pubTimestamp":1649890579,"share":"https://ttm.financial/m/news/1153344302?lang=&edition=fundamental","pubTime":"2022-04-14 06:56","market":"us","language":"en","title":"Skittish Stock Traders Are Bracing for $2 Trillion Option Expiration","url":"https://stock-news.laohu8.com/highlight/detail?id=1153344302","media":"Bloomberg","summary":"BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for ","content":"<div>\n<p>BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for stocks: Katy KaminskiInflation is surging, central banks are on the move and now it’s earnings ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-04-13/skittish-stock-traders-bracing-for-2-trillion-option-expiration?srnd=premium-asia\">Web Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Skittish Stock Traders Are Bracing for $2 Trillion Option Expiration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSkittish Stock Traders Are Bracing for $2 Trillion Option Expiration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-14 06:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-04-13/skittish-stock-traders-bracing-for-2-trillion-option-expiration?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for stocks: Katy KaminskiInflation is surging, central banks are on the move and now it’s earnings ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-04-13/skittish-stock-traders-bracing-for-2-trillion-option-expiration?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/news/articles/2022-04-13/skittish-stock-traders-bracing-for-2-trillion-option-expiration?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153344302","content_text":"BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for stocks: Katy KaminskiInflation is surging, central banks are on the move and now it’s earnings season. To top it all off, stock traders face the market-roiling potential of a monthly options expiration estimated at more than $2 trillion.Roughly $495 billion in single-stock derivatives are set to expire Thursday, with another $980 billion of S&P 500-linked contracts and $170 billion in options tied to the State Street fund tracking the S&P 500 all running out as the holiday-shortened week ends, according to estimates from Goldman Sachs Group Inc.’s Rocky Fishman. Such volumes have been a source of volatility in the past year.While nothing is ever assured in markets, indexes have exhibited a consistent pattern of declining on days when contracts are closed out. This time around, it comes as stocks are suffering through yet another bout of volatility, with the S&P 500 notching only four positive days since the start of the month.It isn’t out of the ordinary to get a monthly expiration on a Thursday in April, but other “wrinkles arise because it can coincide with tax day and the start of earnings season, both of which we’re getting now,” said Steve Sosnick, chief strategist at Interactive Brokers LLC. The deadline for Americans to file their tax returns is April 18.Source: Goldman SachsSource: BloombergWith monetary and fiscal support receding, investors have been hunkering down -- and the mood has turned gloomy. A survey by Bank of America Corp. showed fund-manager optimism about global growth is at a record low. The greatest number since 2008 are predicting a stagflationary period of lower growth and still-high inflation. Sentiment is “poor,” said the bank’s strategist. Managers remain in the “‘sell-the-rally’ camp,” and view previous selloffs as just an “appetizer.”Others are dialing back their optimism. JPMorgan Chase & Co.’s Marko Kolanovic, once a steadfast bull, said investors who previously raised stock holdings should now take profits and shift some money to government bonds. Truist Advisory Services’ Keith Lerner downgraded his view on equities, cutting them to neutral from attractive, while saying that the range of potential economic and market outcomes was “unusually wide.”A cautious stance is prevalent in single-stock data, too. The 20-day average of Cboe’s put-call volume ratio for single stocks has risen from a four-month low, showing an increase in moves to hedge against price drops. Meanwhile, the Cboe Volatility Index, a gauge of prices on S&P 500 options, has swung wildly this month, from as low as 18.6 to as high as 24.37. It was in the middle of that range as of 3:50 p.m. Wednesday.“Given the backdrop of political uncertainty and supply-chain issues, I think it’s not an easy time, particularly for the equity markets,” Katy Kaminski, chief research strategist at AlphaSimplex, said in a phone interview. Inflation, for instance, “has more room to run than most people would like to think. They keep thinking everything is just going to go back to normal and I think it could take quite a while.”Mushrooming options volume has been a regular feature of post-pandemic markets. Bullish options contracts became a favorite tool of retail traders who spent the Covid lockdowns trading from their phones. Now, amid choppier markets, demand for bearish options has been growing. Contracts tied to declines in State Street’s S&P 500 ETF and the iShares iBoxx High Yield Corporate Bond ETF have started to rise again, with put open interest on the high-yield fund surging.To be sure, Chris Murphy, co-head of derivatives strategy at Susquehanna International Group, said there is now likely to be less single-stock impact than in the day-trading frenzy of the past two years. Investors who bought puts in January and February when the market was selling off are way out of the money now, he said, which could mute the impact of expirations on market moves.His team says a total of 85 million U.S.-listed option contracts are set to expire Thursday, an 8% decrease from a year ago. Single-stock contracts are down 12% year-over-year. “We are seeing a lot less of the meme stock trading compared to last year, that’s the major culprit,” Murphy said.Source: Susquehanna, IVolatilitySource: BloombergMeanwhile, index and ETF contracts increased 7% and 3%, respectively, versus year-earlier levels. “This is likely due to more of a focus on the macro environment and more hedging,” he said.","news_type":1,"symbols_score_info":{".SPX":0,"NQmain":0,"YMmain":0,".IXIC":0,"ESmain":0,".DJI":0}},"isVote":1,"tweetType":1,"viewCount":2536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003975436,"gmtCreate":1640867568065,"gmtModify":1676533549171,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3585210989099593","idStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003975436","repostId":"1161715768","repostType":4,"isVote":1,"tweetType":1,"viewCount":1984,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003928423,"gmtCreate":1640856403288,"gmtModify":1676533548278,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3585210989099593","idStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003928423","repostId":"2195454191","repostType":4,"repost":{"id":"2195454191","kind":"highlight","pubTimestamp":1640852195,"share":"https://ttm.financial/m/news/2195454191?lang=&edition=fundamental","pubTime":"2021-12-30 16:16","market":"us","language":"en","title":"Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2195454191","media":"Motley Fool","summary":"These two stocks could provide life-changing returns in 10 years.","content":"<div>\n<p>The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/\">Web Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million? Buy and Hold These 2 Stocks for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 16:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCS":"Doximity, Inc.","BK4139":"生物科技","BK4167":"医疗保健技术","BK4551":"寇图资本持仓","BK4539":"次新股"},"source_url":"https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2195454191","content_text":"The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two stocks that could outperform the market and provide multibagger returns over the next decade.If you add Doximity (NYSE:DOCS) and DermTech (NASDAQ:DMTK) to a diversified portfolio, they could help you turn $100,000 into $1 million over the next decade. Here's how.Image source: Getty ImagesDoximity: A doctor's social mediaWhile many business professionals use Microsoft's LinkedIn, nearly 80% of medical professionals in the U.S. use Doximity. Doximity serves as a career growth app, a messaging app, an educational resource, and a social media platform all in one for doctors. In addition, Doximity offers telehealth accessibility, making it the super app for doctors and healthcare professionals.Doximity has truly become a primary platform that medical professionals use. Aside from the 80% of doctors on the platform, 50% of nurse practitioners and physician assistants use it, and a staggering 90% of medical students use it -- signaling that Doximity will continue to be the place where medical workers should go to collaborate, communicate, and expand their careers. As a result, Doximity's platform has attracted lots of advertisers.Doximity makes money from advertising revenue from pharmaceutical companies looking to show doctors their drugs on the research part of its app that delivers personalized news and research to doctors. Over 600 pharmaceutical companies are desperate to get their products in front of doctors and potential buyers, 200 of which spend over $100,000 per year to do so. What is most impressive is that Doximity's net retention rate is 173% -- meaning these customers spent 73 cents more in Q3 2021 on top of every dollar they spent in the year-ago quarter, including churning customers.In addition, 93% of Doximity's revenue comes from subscriptions from pharmaceutical companies. Because of this focus on subscriptions, its gross margins are a lofty 89%. Another factor making this company a financial powerhouse is the 80% share of U.S, doctors already on the platform, which means Doximity does not have to spend a ton on operating expenses. This allows for Doximity to bring tons of cash to the bottom line: In Q3, it had $36 million in net income -- representing 45% of revenue. And as if this couldn't get any better, the company also generated $18 million in free cash flow in Q3.In addition to this impressive profitability, the company has been able to consistently grow its top line at 76% year over year. It's not hard to see why shares trade at a staggering 184 times earnings and 36 times sales. However, this company has a dominant foothold in this market, with the majority of its consumer base on the platform, making advertising space nearly invaluable. This position has already led to growth and profitability, that I think could continue for the next decade.DermTech: A different approach to skin cancerDermTech is riskier than Doximity, but its growth potential is even larger. DermTech has created a new way to test for skin cancer that is easier, cheaper, and more accurate than the traditional biopsy. Instead of having a chunk of skin taken out, DermTech's PLA Test can simply be put on the area of concern like a bandage, and results are given within 72 hours. The chance of missing melanoma drops from 17% to 1% with DermTech.Where DermTech has major growth potential is with its insurance coverage. While the company's product is not currently insured by the big insurance companies, it expects to obtain coverage in late 2022 or early 2023. If the company can get major insurance coverage, that could make it easier for doctors to switch over to its product.Even without major coverage, the company is seeing impressive growth. Test revenue grew 140% year over year, and the company's sample volume reached 11,720, growing 75% year over year in Q3.The company is nowhere near profitability, having lost almost seven times its revenue in Q3, but with just a $485 million market capitalization, it would be unrealistic to expect profitability at this stage. DermTech does, however, have over $204 million in cash and cash equivalents to subsidize its losses for some time. The company has only brought in $8.7 million in 2021, yet it has a market opportunity of over $10 billion. With such a large opportunity and a superior product, it is understandable that the company is valued at 40 times sales.While its current valuation and unprofitability aren't appealing, the company could potentially grow its revenue by 100 times and still be scratching the surface of its addressable market. With this much potential, adding DermTech into a diversified portfolio could be a move that -- if it plays out -- could create portfolio-changing (and life-changing) results.","news_type":1,"symbols_score_info":{"DMTK":1,"DOCS":1}},"isVote":1,"tweetType":1,"viewCount":1646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003928283,"gmtCreate":1640856376009,"gmtModify":1676533548262,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3585210989099593","idStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003928283","repostId":"1198596106","repostType":4,"repost":{"id":"1198596106","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640855595,"share":"https://ttm.financial/m/news/1198596106?lang=&edition=fundamental","pubTime":"2021-12-30 17:13","market":"us","language":"en","title":"Biogen Dropped 5% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1198596106","media":"Tiger Newspress","summary":"U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying","content":"<html><head></head><body><p>U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.<img src=\"https://static.tigerbbs.com/0d21708fdbb17a292f7748f78750b030\" tg-width=\"1121\" tg-height=\"718\" referrerpolicy=\"no-referrer\"/>Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was &#34;not true,&#34; without giving any more details.</p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p>In June, Biogen&#39;s controversial Alzheimer&#39;s drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel&#39;s view that the company had not proven the treatment&#39;s clinical benefits.</p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug&#39;s high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Dropped 5% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Dropped 5% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-30 17:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.<img src=\"https://static.tigerbbs.com/0d21708fdbb17a292f7748f78750b030\" tg-width=\"1121\" tg-height=\"718\" referrerpolicy=\"no-referrer\"/>Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was &#34;not true,&#34; without giving any more details.</p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p>In June, Biogen&#39;s controversial Alzheimer&#39;s drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel&#39;s view that the company had not proven the treatment&#39;s clinical benefits.</p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug&#39;s high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198596106","content_text":"U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was \"not true,\" without giving any more details.Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":1263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}